stockrow
Friday 6 November 2026
Export KNSA’s income statement to Excel — free account
Kiniksa Pharmaceuticals International, plc
KNSA Healthcare Drug Manufacturers Specialty & Generic
Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.
- Revenue
- +58.1%
- EPS
- +142.2%
- Free cash flow
- +43.5%
Quarter to September 2026, against a year earlier
93.68
5.34
+6.04%
Follow KNSA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 39 | 220 | 270 | 423 | 678 | 946 | +104.8% | 1,050 | 1,304 | 1,502 | +30.4% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.39 | 89.60 | 87.64 | 85.61 | 88.54 | 90.16 | +88.5 pt | ||||||
| EBT | (24) | (65) | (103) | (164) | (156) | (157) | 11 | (17) | (36) | 89 | 146 | n/m | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (406.13) | 5.01 | (6.16) | (8.54) | 13.12 | 15.45 | +13.1 pt | ||||||
| Net income | (24) | (65) | (103) | (162) | (161) | (158) | 183 | 14 | (43) | 59 | 110 | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.56 | 3.17 | 3.86 | 5.93 | 9.13 | 12.10 | n/m | |||||
| Earnings | (91.61) | (35.84) | (3.49) | (2.99) | (2.61) | (2.30) | 2.64 | 0.20 | (0.60) | 0.80 | 1.43 | n/m | ||||||
| Cash flow | (83.56) | (27.75) | (2.74) | (2.93) | (2.21) | (1.84) | 0.08 | 0.19 | 0.36 | 1.86 | 2.54 | n/m | ||||||
| Capex | (0.01) | (0.04) | (0.18) | (0.06) | 0.00 | (0.30) | 0.00 | 0.00 | 0.00 | (0.02) | (0.02) | +7.0% | ||||||
| Free cash flow | (83.57) | (27.78) | (2.92) | (2.99) | (2.21) | (2.14) | 0.08 | 0.19 | 0.36 | 1.84 | 2.52 | n/m | ||||||
| Book value | 206.97 | 16.61 | 9.45 | 4.17 | 5.04 | 2.70 | 5.71 | 6.26 | 6.14 | 7.65 | 9.08 | (30.7%) | ||||||
| Shares, m | 0 | 2 | 30 | 54 | 62 | 69 | 69 | 70 | 71 | 74 | 77 | +87.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 5.47 | 97.53 | 0.00 | 51.56 | 62.08 | 30.9 | |||||
| P/S | — | — | — | — | — | 0.00 | 4.55 | 4.80 | 3.34 | 4.52 | 7.32 | 3.4 | ||||||
| P/B | — | — | — | — | — | 4.36 | 2.53 | 2.96 | 3.22 | 5.39 | 9.74 | 3.7 | ||||||
| EV/Sales | — | — | — | — | — | 0.00 | 3.68 | 4.04 | 2.76 | 3.91 | 6.71 | 2.9 | ||||||
| EV/FCF | — | — | — | — | — | (4.26) | 144.02 | 82.33 | 45.80 | 19.39 | 32.19 | 57.5 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (22) | (50) | (81) | (158) | (137) | (126) | 6 | 13 | 26 | 138 | 199 | n/m | |||||
| Capex | 0 | 0 | (5) | (3) | 0 | (20) | 0 | 0 | 0 | (2) | (2) | +100.5% | ||||||
| Free cash flow | (22) | (50) | (86) | (162) | (137) | (147) | 6 | 13 | 25 | 136 | 197 | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 54 | 30 | 271 | 214 | 301 | 152 | 196 | 213 | 231 | 388 | 558 | +24.5% | |||||
| Net debt | (56) | (46) | (307) | (233) | (324) | (182) | (191) | (206) | (244) | (414) | (569) | +24.9% | ||||||
| Shareholders’ equity | 54 | 30 | 279 | 225 | 312 | 185 | 396 | 439 | 438 | 568 | 710 | +29.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (46.12) | (124.80) | (55.88) | (56.16) | (53.44) | (54.24) | 52.96 | 2.86 | (7.80) | 8.78 | 12.92 | +54.9 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (3,451.96) | 2.97 | (6.77) | (14.63) | 31.44 | 57.65 | +31.4 pt | ||||||
| ROE | 41.53 | 112.39 | (108.91) | (64.15) | (60.06) | (63.55) | 63.10 | 3.37 | (9.85) | 11.73 | 17.59 | (29.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 47 | 111 | 137 | 168 | 215 | 220 | 297 | 315 | 366 | — | +29.2% | |||||
| Revenue/emp, $m | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 1.00 | 0.91 | 1.34 | 1.85 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026
Business profile
Where the money comes from and where it goes Fiscal 2025
| Pharmaceutical | 678 | 100.00% |
|---|---|---|
| Gross margin | 88.54% | |
| Operating margin | 11.40% | |
| Pre-tax margin | 13.12% |
Kiniksa Pharmaceuticals International, plc vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Ltd | $12.1B | 44.4× | 30.7× | −10.09% (below 0%: shrinking) | −36.84% (below 0%: shrinking) | −70.49% (below 0%: shrinking) | 52.13% | 14.63% | Compare |
| ELAN Elanco Animal Health Incorporated | $11.8B | — (loss-making) | 161× | +10.23% (above 0%: growing) | n/m | +35.56% (above 0%: growing) | 58.33% | 7.97% | Compare |
| ALKS Alkermes plc | $7.5B | — (loss-making) | — (loss-making) | +21.80% (above 0%: growing) | −80.60% (below 0%: shrinking) | +6.78% (above 0%: growing) | 80.38% | 7.50% | Compare |
| KNSA Kiniksa Pharmaceuticals International, plc | $6.9B | 62.1× | 67.8× | +58.12% (above 0%: growing) | +142.20% (above 0%: growing) | +43.51% (above 0%: growing) | 90.29% | 18.97% | |
| AMRX AMNEAL PHARMACEUTICALS, INC. | $6.8B | 36.9× | 44.2× | +9.96% (above 0%: growing) | +267.00% (above 0%: growing) | −50.92% (below 0%: shrinking) | 38.73% | 11.06% | Compare |
| LNTH Lantheus Holdings, Inc. | $6.6B | 24.3× | 21.3× | +1.54% (above 0%: growing) | −17.07% (below 0%: shrinking) | +7.71% (above 0%: growing) | 62.43% | 8.26% | Compare |
| HIMS Hims & Hers Health, Inc. | $5.6B | — (loss-making) | — (loss-making) | +38.25% (above 0%: growing) | n/m | +5.09% (above 0%: growing) | 63.83% | (12.90%) | Compare |
| SUPN Indivior Pharmaceuticals Inc. | $5.6B | 7.6× | 9.5× | +13.38% (above 0%: growing) | +241.47% (above 0%: growing) | +240.68% (above 0%: growing) | 85.67% | 50.84% | Compare |
| LQDA Liquidia Corporation | $4.0B | 28.5× | 22.1× | +1,842.73% (above 0%: growing) | n/m | +270.23% (above 0%: growing) | 93.27% | 49.81% | Compare |
| Median of peers | $6.7B | 28.5× | 26.4× | +11.81% | −17.07% | +7.25% | 63.13% | 9.66% |
From the latest earnings call
- CEO Sanj K. Patel said ARCALYST reached 23% of the annual multiple-recurrence patient population by quarter-end, as prescribing and patient adoption expanded.
- Patel said the KPL-387 pivotal trial was enrolling and dosing patients, with data expected in the second half of 2027.
Pay and ownership Proxy statement filed 16 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 10.78m | 28.44m | 233.45 |
| 2024 | 7.01m | 8.70m | 111.94 |
| 2023 | 5.30m | 6.80m | 98.75 |
| 2022 | 6.11m | 8.73m | 84.78 |
| 2021 | 6.59m | 579.47k | 66.61 |
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Read the proxy statement
Kiniksa Pharmaceuticals International, plc (KNSA) Latest News
27 Oct
29 Jul
28 Jul
1 May
29 Apr
KNSA metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
Kiniksa Pharmaceuticals International is a biopharmaceutical company focused on cardiovascular diseases. It sells ARCALYST in the United States, primarily for recurrent pericarditis, an inflammatory disease in which the sac surrounding the heart becomes inflamed again after an earlier episode. The company’s chief executive officer is Sanj K. Patel.
ARCALYST blocks two inflammatory signaling proteins, IL-1α and IL-1β. Patients receive it as a weekly injection under the skin. It is approved in the United States for recurrent pericarditis in adults and children 12 years and older. It is also approved for certain rare inflammatory conditions known as CAPS and for maintenance of remission in DIRA, subject to age or weight requirements.